Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.

MLA

Mayer, Erica L., et al. “Palbociclib with Adjuvant Endocrine Therapy in Early Breast Cancer (PALLAS): Interim Analysis of a Multicentre, Open-Label, Randomised, Phase 3 Study.” Lancet Oncology, vol. 22, no. 2, Feb. 2021, pp. 212–22. EBSCOhost, https://doi.org/10.1016/S1470-2045(20)30642-2.

APA

Mayer, E. L., Dueck, A. C., Martin, M., Rubovszky, G., Burstein, H. J., Bellet-Ezquerra, M., Miller, K. D., Zdenkowski, N., Winer, E. P., Pfeiler, G., Goetz, M., Ruiz-Borrego, M., Anderson, D., Nowecki, Z., Loibl, S., Moulder, S., Ring, A., Fitzal, F., Traina, T., & Chan, A. (2021). Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 22(2), 212–222. https://doi.org/10.1016/S1470-2045(20)30642-2

Chicago

Mayer, Erica L, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerra, Kathy D Miller, et al. 2021. “Palbociclib with Adjuvant Endocrine Therapy in Early Breast Cancer (PALLAS): Interim Analysis of a Multicentre, Open-Label, Randomised, Phase 3 Study.” Lancet Oncology 22 (2): 212–22. doi:10.1016/S1470-2045(20)30642-2.